Johnson & Johnson Launches VIRTUGUIDEā� AI-Powered Patient-Matched Lapidus System in U.S. to Reduce Complexity in Bunion Surgery for Millions
Johnson & Johnson (NYSE:JNJ) has launched the VIRTUGUIDEā� System, an AI-powered solution for bunion surgery that received FDA 510(k) clearance earlier this year. The system, designed for Lapidus procedures, uses pre-operative planning software developed with PeekMedĀ® to create personalized surgical recommendations.
Early adopters report 30-minute reductions in surgical time compared to traditional techniques. The technology addresses a significant medical need, as bunions affect approximately one-third of U.S. adults. The VIRTUGUIDEā� System joins J&J's VELYSā� Enabling Tech solutions portfolio, aiming to streamline surgical procedures and improve accuracy through patient-matched instrumentation.
Johnson & Johnson (NYSE:JNJ) ha lanciato il Sistema VIRTUGUIDEā�, una soluzione basata sull'intelligenza artificiale per la chirurgia del alluce valgo, che ha ottenuto l'autorizzazione FDA 510(k) all'inizio di quest'anno. Il sistema, progettato per le procedure di Lapidus, utilizza un software di pianificazione pre-operatoria sviluppato con PeekMedĀ® per creare raccomandazioni chirurgiche personalizzate.
I primi utilizzatori segnalano una riduzione di 30 minuti nel tempo chirurgico rispetto alle tecniche tradizionali. Questa tecnologia risponde a una necessitĆ medica importante, dato che l'alluce valgo colpisce circa un terzo degli adulti statunitensi. Il Sistema VIRTUGUIDEā� si aggiunge al portafoglio di soluzioni VELYSā� Enabling Tech di J&J, con l'obiettivo di semplificare le procedure chirurgiche e migliorare la precisione grazie a strumenti personalizzati per il paziente.
Johnson & Johnson (NYSE:JNJ) ha lanzado el Sistema VIRTUGUIDEā�, una soluciĆ³n impulsada por inteligencia artificial para la cirugĆa de juanetes que recibiĆ³ la aprobaciĆ³n FDA 510(k) a principios de este aƱo. El sistema, diseƱado para procedimientos Lapidus, utiliza un software de planificaciĆ³n preoperatoria desarrollado con PeekMedĀ® para crear recomendaciones quirĆŗrgicas personalizadas.
Los primeros usuarios reportan una reducciĆ³n de 30 minutos en el tiempo quirĆŗrgico en comparaciĆ³n con las tĆ©cnicas tradicionales. La tecnologĆa responde a una necesidad mĆ©dica significativa, ya que los juanetes afectan aproximadamente a un tercio de los adultos en EE.UU.. El Sistema VIRTUGUIDEā� se une al portafolio de soluciones VELYSā� Enabling Tech de J&J, con el objetivo de optimizar los procedimientos quirĆŗrgicos y mejorar la precisiĆ³n mediante instrumentaciĆ³n adaptada al paciente.
Johnson & Johnson (NYSE:JNJ)ė� ģ¬ķ“ ģ“� FDA 510(k) ģ¹ģøģ� ė°ģ ģ”±ģ ź·¼ė§ģ� ģģ ģ� AI źø°ė° ģė£Øģ ģø VIRTUGUIDEā� ģģ¤ķ �ģ� ģ¶ģķģµėė¤. ģ� ģģ¤ķ ģ Lapidus ģģ ģ ģ°Øė„� ģķ“ ģ¤ź³ėģģ¼ė©°, PeekMedĀ®ź³� ķØź» ź°ė°ķ� ģģ ģ � ź³ķ ģķķøģØģ“ė„¼ ģ¬ģ©ķģ¬ ź°ģø ė§ģ¶¤ķ� ģģ ź¶ź³ ģģ ģ ź³µķ©ėė�.
ģ“źø° ģ¬ģ©ģė¤ģ źø°ģ”“ źø°ė²ģ� ė¹ķ“ ģģ ģź°ģ� 30ė¶� ėØģ¶ėģė¤ź³ ė³“ź³ ķ©ėė�. ģ� źø°ģ ģ ėÆøźµ ģ±ģøģ� ģ� 3ė¶ģ 1ģ� ģ”±ģ ź·¼ė§ģ¼ģ¼ė”� ź³ ķµė°ė ģ¤ģķ� ģė£ ģģė„� ķ“ź²°ķ©ėė�. VIRTUGUIDEā� ģģ¤ķ ģ J&Jģ� VELYSā� Enabling Tech ģė£Øģ � ķ¬ķøķ“ė¦¬ģ¤ģ ķ©ė„ķģ¬, ķģ ė§ģ¶¤ķ� źø°źµ¬ė„� ķµķ“ ģģ ģ ģ°Øė„� ź°ģķķź³� ģ ķģ±ģ ķ„ģģķ¤ė� ź²ģ ėŖ©ķė”� ķ©ėė�.
Johnson & Johnson (NYSE:JNJ) a lancĆ© le SystĆØme VIRTUGUIDEā�, une solution alimentĆ©e par l'intelligence artificielle pour la chirurgie des oignons, qui a reƧu l'autorisation FDA 510(k) plus tĆ“t cette annĆ©e. Ce systĆØme, conƧu pour les procĆ©dures de Lapidus, utilise un logiciel de planification prĆ©opĆ©ratoire dĆ©veloppĆ© avec PeekMedĀ® pour crĆ©er des recommandations chirurgicales personnalisĆ©es.
Les premiers utilisateurs rapportent une rĆ©duction de 30 minutes du temps opĆ©ratoire par rapport aux techniques traditionnelles. Cette technologie rĆ©pond Ć un besoin mĆ©dical important, car les oignons affectent environ un tiers des adultes amĆ©ricains. Le SystĆØme VIRTUGUIDEā� rejoint le portefeuille de solutions VELYSā� Enabling Tech de J&J, visant Ć simplifier les procĆ©dures chirurgicales et Ć amĆ©liorer la prĆ©cision grĆ¢ce Ć une instrumentation adaptĆ©e au patient.
Johnson & Johnson (NYSE:JNJ) hat das VIRTUGUIDEā� System eingefĆ¼hrt, eine KI-gestĆ¼tzte Lƶsung fĆ¼r die Operation von Hallux valgus, die Anfang dieses Jahres die FDA 510(k) Zulassung erhalten hat. Das System, das fĆ¼r Lapidus-Verfahren entwickelt wurde, verwendet eine prƤoperative Planungssoftware, die in Zusammenarbeit mit PeekMedĀ® entwickelt wurde, um personalisierte chirurgische Empfehlungen zu erstellen.
Erstanwender berichten von 30 Minuten kĆ¼rzeren Operationszeiten im Vergleich zu herkƶmmlichen Techniken. Die Technologie adressiert einen bedeutenden medizinischen Bedarf, da Hallux valgus etwa ein Drittel der erwachsenen US-Bevƶlkerung betrifft. Das VIRTUGUIDEā� System ergƤnzt das VELYSā� Enabling Tech Lƶsungsportfolio von J&J, mit dem Ziel, chirurgische AblƤufe zu optimieren und die Genauigkeit durch patientenangepasste Instrumente zu verbessern.
- None.
- None.
Insights
J&J's VIRTUGUIDEā� AI system streamlines bunion surgery with patient-matched precision, potentially impacting a large market while reducing OR time.
Johnson & Johnson's new VIRTUGUIDEā� System represents a significant advancement in orthopedic surgical technology, specifically targeting Lapidus procedures for bunion correction. The AI-powered, patient-matched solution addresses a substantial market opportunity, considering bunions affect approximately one-third of U.S. adultsātranslating to roughly 110 million Americans.
The system's value proposition centers on reducing surgical complexity through personalized pre-operative planning and customized instrumentation. Early adopters report procedural time savings of at least 30 minutes compared to traditional techniques, which translates to significant operating room efficiency gains. This time reduction could potentially allow for more procedures per day, benefiting both healthcare facilities and patients through reduced anesthesia exposure.
From a technical perspective, the VIRTUGUIDEā� System leverages the PeekMedĀ® collaboration to create personalized surgical recommendations, suggesting J&J is prioritizing strategic partnerships to accelerate innovation in its orthopedic portfolio. The system's recent FDA 510(k) clearance validates its safety profile and positions it for immediate commercialization.
This launch strengthens J&J's position in the extremities segment of orthopedics, complementing their broader VELYSā� technology ecosystem. For a company generating approximately
Early VIRTUGUIDEā� surgeons report a 30-minute reduction in surgical time versus traditional treatment1,2,*,**
Bunions are among the most common foot problems, affecting nearly one-third of adults in the
"VIRTUGUIDEā� has completely transformed my approach to bunion surgery, making a complex Lapidus procedure significantly easier and faster. Since adopting VIRTUGUIDEā�, my surgical corrections have been spot-onāwhat I plan preoperatively is exactly what I achieve in the operating room," said Michael Campbell, M.D., FAAOS, a board-certified orthopaedic surgeon at Atlantic Orthopaedic Specialists.Ā± "This improved accuracy leads to better outcomes, and the ability to present the pre-operative plan to my patients helps address their questions and ease their concernsĀ§."
"The VIRTUGUIDEā� System is a pivotal advancement in AI-powered surgical precision for treating bunion deformitiesāa common, painful, and potentially debilitating condition affecting nearly one-third of Americans4," said Oray Boston, Worldwide President of Trauma, Extremities, Craniomaxillofacial, Animal Health and Sports Medicine, Orthopaedics,ĢżJohnson & JohnsonĢżMedTech. "This milestone marks an important step forward, as VIRTUGUIDEā� becomes the latest addition to our growing portfolio of VELYSā� Enabling Tech solutions. By automating surgical planning and tailoring instrumentation to each patient, the system helps reduce complexity in the operating room and helps surgeons to achieve the intended correction2,7**."
This launch follows the 510(k) clearance from the
Orthopaedic Solutions from Johnson & Johnson MedTechĢż
Across Johnson & Johnson, we are tackling the world's most complex and pervasive health challenges. In Orthopaedics, we are on a mission to keep people moving by leveraging our deep expertise in joint reconstruction, robotics and enabling tech, spine, sports, trauma, and extremities, to develop the next generation of medtech solutions. We offer one of the most comprehensive Orthopaedics portfolios in the world that helps heal and restore movement for the millions of patients we serve. For more, visit our Ģżor follow us on .Ģż
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more about our MedTech sector's global scale and deep expertise in cardiovascular, orthopaedics, surgery and vision solutions at . Follow us at Ģżand on . DePuy Synthes Products, Inc. is a Johnson & Johnson company.
Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding the VIRTUGUIDEā� System. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns of purchasers of health care products and services; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at , Ģżor on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
Important Information: Prior to use, refer to the instructions for use supplied with the device(s) or indications, contraindications, warnings and precautions.
Ā© Johnson & Johnson and its affiliates 2025. All rights reserved. US_ORT_FTAK_398543
* Statements are based on responses from 10 surgeons, having completed a total of 150 Lapidus procedures using the VIRTUGUIDEā� System. The statements reflect surgeon experience, not clinical outcomes, and were included if at least 6 surgeons agreed.
** VIRTUGUIDEā� System compared to Treace Medical LapiplastyĀ® 3-Plane System and Paragon28 Bun-Yo-Matic Lapidus Clamp System.
Ā± Dr. Michael Campbell, M.D., FAAOS is a paid consultant for Johnson & Johnson MedTech.
Ā§These statements reflect the experience, approach and opinion of the surgeon.
āĢżThe VIRTUGUIDEā� Planning Software, powered by PeekMedĀ®, is developed and owned by Peek Health, S.A. Refer to help.peekmed.com for user manuals, FAQ's, or any support.
The third-party trademarks used herein are trademarks of their respective owners.
1ĢżJohnson & Johnson MedTech, VIRTUGUIDEā� System Early Surgeon Experience Report December 2024, Windchill Document# EM24-0028
2ĢżJohnson & Johnson and its affiliatesĢżVIRTUGUIDEā� System Feature Memo. 9th Dec 2024. Windchill # EM24-0027.
3ĢżAmerican Orthopaedic Foot & Ankle Society. Lapidus Procedure. FootCareMD. Accessed June 24, 2025. Ģż
4ĢżMedlinePlus. Bunion: Genetic and Environmental Causes.
5ĢżRupke T. The modified Lapidus procedure for the treatment of moderate to severe hallux valgus. Orthogate. Published October 30, 2013. Accessed June 26, 2025.
6ĢżForan IM, Lin J, Hamid KS, Lee S. Technical tip: kerfing for Lapidus arthrodesis: deformity correction with minimal bone resection. J Foot Ankle Surg. 2021;60(2):424-427. doi:10.1053/j.jfas.2020.10.004
7ĢżSobrĆ³n FB, Santos-Vaquinhas AD, Alonso B, et al. Technique tip: 3D printing surgical guide for pes cavus midfoot osteotomy. J Foot and Ankle Surgery. 2022;28:371-377.Ģż
Media Contacts:
Erin Farley
[email protected]
AbhiĢżBasu
[email protected]
Investor Contact:
[email protected]
View original content to download multimedia:
SOURCE Johnson & Johnson MedTech
FAQ
What is the VIRTUGUIDEā� System by Johnson & Johnson (NYSE:JNJ)?
How much time does the VIRTUGUIDEā� System save during bunion surgery?
When did Johnson & Johnson receive FDA clearance for VIRTUGUIDEā�?
What percentage of U.S. adults are affected by bunions?
How does VIRTUGUIDEā� improve bunion surgery outcomes?
